Vanderbilt-Ingram Cancer Center
vicc.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
217
Active
37
Phase 3
4
Total enrollment
64,177
Pipeline matrix
Showing 36 of 36 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Lutetium Lu 177 Dotatate | — | — | — | — | — | 1 | |
| Copper Cu 64 Dotatate | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | — | 7 | ||
| Carboplatin | — | — | — | — | — | 9 | |
| Atezolizumab | — | — | — | — | — | 4 | |
| Pembrolizumab | — | — | — | — | — | 4 | |
| Ipilimumab | — | — | — | — | — | 2 | |
| Etoposide | — | — | — | — | — | 2 | |
| nab-paclitaxel | — | — | — | — | — | 2 | |
| Nemtabrutinib | — | — | — | — | — | 1 | |
| Brexucabtagene autoleucel | — | — | — | — | — | 1 | |
| Neratinib | — | — | — | — | — | 1 | |
| Cabozantinib | — | — | — | — | — | 1 | |
| Rigosertib | — | — | — | — | — | 1 | |
| Sacituzumab Govitecan | — | — | — | — | — | 1 | |
| Pemetrexed | — | — | — | — | — | 1 | |
| Cemiplimab | — | — | — | — | — | 1 | |
| letrozole | — | — | — | 8 | |||
| cetuximab | — | — | — | — | 3 | ||
| Panitumumab | — | — | — | — | 2 | ||
| Nivo800 | — | — | — | — | — | 1 | |
| Panitumumab IRDye 800 | — | — | — | — | — | 1 | |
| PI3K inhibitor BYL719 | — | — | — | — | — | 1 | |
| 18F-NOTA-ABY-030 | — | — | — | — | — | 1 | |
| Trametinib treatment | — | — | — | — | — | 1 | |
| Eltanexor | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | — | 1 | |
| Panitumumab-IRDye800 | — | — | — | — | — | 1 | |
| 18F-fluoromisonidazole | — | — | — | — | — | 1 | |
| [68Ga]Ga-ABY-025 | — | — | — | — | — | 1 | |
| protein expression analysis | — | — | — | — | 11 | ||
| gene expression analysis | — | — | — | — | 8 | ||
| microarray analysis | — | — | — | — | — | 4 | |
| comparative genomic hybridization | — | — | — | — | — | 2 | |
| gene expression microarray analysis | — | — | — | — | — | 1 | |
| proteomic profiling analysis | — | — | — | — | — | 1 |
Next readouts
- 2014-12
- 2024-12
- 2026-02-01
- 2026-10-01
- 2026-11-30
- 2027-01-31
- 2027-02-01
- 2027-05-28
- 2027-06-30
- 2027-12
Top conditions
- Breast Cancer27
- Lung Cancer24
- Head and Neck Cancer22
- Solid Tumor10
- Lymphoma10
- Colorectal Cancer9
- Leukemia7
- Multiple Myeloma and Plasma Cell Neoplasm7
Frequently asked questions about Vanderbilt-Ingram Cancer Center
- How many clinical trials does Vanderbilt-Ingram Cancer Center have on ClinicalTrials.gov?
- Vanderbilt-Ingram Cancer Center is listed as the lead sponsor on 217 clinical trials in ClinicalTrials.gov, 37 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Vanderbilt-Ingram Cancer Center's trials are in Phase 3?
- 4 of Vanderbilt-Ingram Cancer Center's trials are in Phase 3, spread across 36 active drug programs.
- What therapeutic areas does Vanderbilt-Ingram Cancer Center focus on?
- Vanderbilt-Ingram Cancer Center's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Lung Cancer, Head and Neck Cancer, Solid Tumor, Lymphoma.
- When are Vanderbilt-Ingram Cancer Center's next clinical trial readouts?
- Vanderbilt-Ingram Cancer Center has 10 upcoming primary-completion readouts tracked here; the soonest is “BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer”, expected around 2014-12.